Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/BioNTech downgraded to Sell amid COVID vaccine revenue drop and pipeline doubts

BNTX

$91.90

-$0.09 -0.10%

BioNTech downgraded to Sell amid COVID vaccine revenue drop and pipeline doubts

Company Fundamentals

06 May 2026

Seeking Alpha

View Source

Bearish

BioNTech SE has been downgraded to Sell due to declining revenues from its COVID vaccine, leadership departures, and uncertainties in its drug pipeline. The company reported a €531.9 million net loss in Q1 and expects revenues of €2–3 billion by 2026. It is undertaking major staff cuts and site closures to save €500 million annually, supporting a strategic shift towards oncology. However, challenges with its key oncology asset pumitamig and overall weak pipeline prospects raise concerns about the stock's current valuation.

More News (BNTX)

Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.

The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...

Market News

Bullish

2 days ago